资讯
As antibiotic-resistant "superbugs" make infections trickier to treat, some in the medical community are turning to ...
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance ...
呼吸与危重症医学科现已形成门诊、RICU、呼吸介入诊疗中心、睡眠呼吸诊疗室,全域肺功能中心、普通病区及平疫转换病区等一体化诊疗格局。常规开展气管镜检查及介入治疗、经皮支气管动脉栓塞术、多导睡眠呼吸监测、呼吸机辅助通气、肺功能检查及呼出气一氧化氮检查等 ...
22 小时
Vietnam Investment Review on MSNBrii Biosciences announces licensing agreement with Joincare Group for BRII 693 in Greater ...Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today ...
INTRODUCTION The aminoglycosides tobramycin, gentamicin, and amikacin are commonly used to treat hospital-acquired infections caused by Pseudomonas aeruginosa. These infections generally require ...
Pseudomonas, which is present in the recalled batches of Topo Chico water, may cause pneumonia, bloodstream infections, and other severe complications. Coca-Cola has issued a voluntary recall of ...
Braz J Med Biol Res, January 2004, Volume 37 (1) 77-82 Typing of Pseudomonas aeruginosa from hospitalized patients: a comparison of susceptibility and biochemical profiles with genotype A.L. Freitas 1 ...
Symptoms vary, but can include chills, earache, diarrhea, red eyes, difficulty breathing, urinary incontinence and itchy skin. Because a P. aeruginosa infection can potentially cause sepsis, which ...
Purpose. The appropriateness of combination therapy for infections caused by gram-negative organisms is examined. Summary. Mortality from Pseudomonas aeruginosa infection is particularly high ...
Common bacteria use chemical signals to assess their cell density in a process called quorum sensing (QS). The pathogen Pseudomonas aeruginosa utilizes QS to control many virulence factors and traits ...
The growth of the complicated urinary tract infections market is expected to be mainly driven by the entry of new therapies such as Tebipenem Pivoxil Hydrobromide (SPR994), ZAYNICH ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果